I think there is more to it than that to attract the right class of investors and the larger US market. Also US typically values biotechs more highly as a recognised asset class.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.010(2.90%) |
Mkt cap ! $37.50M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.5¢ | 33.5¢ | $148.7K | 432.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 44977 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 19070 | 6 |
View Market Depth
| Last trade - 12.27pm 07/08/2025 (20 minute delay) ? |
| LTP (ASX) Chart |